Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren’s syndrome

Erika Huijser1, Jens Göpfert2, Zana Brkic3, Cornelia G. van Helden-Meeuwsen1, Sanne Jansen1, Thomas Mandl4, Peter Olsson4, Benjamin Schrijver1,5, Marco W.J. Schreurs1,5, Paul L.A. van Daele1,3, Willem A. Dik1,5,* and Marjan A. Versnel1,*

Abstract

Objectives. Type I IFN (IFN-I) activation is a prominent feature of primary SS (pSS), SLE and SSc. Ultrasensitive single-molecule array (Simoa) technology has facilitated the measurement of subfemtomolar concentrations of IFNs. Here we aimed to measure IFN-α2 in serum from pSS, SLE and SSc using a Simoa immunoassay and correlate these levels to blood IFN-stimulated gene (ISG) expression and disease activity.

Methods. Serum IFN-α2 was measured in patients with pSS (n = 85 and n = 110), SLE (n = 24) and SSc (n = 23) and healthy controls (HCs; n = 68) using an IFN-α Simoa assay on an HD-X analyser. IFN-I pathway activation was additionally determined from serum by an IFN-I reporter assay and paired samples of whole blood ISG expression of IFI44, IFI44L, IFIT1, IFIT3 and MxA by RT-PCR or myxovirus resistance protein 1 (MxA) protein ELISA.

Results. Serum IFN-α2 levels were elevated in pSS (median 61.3 fg/ml) compared with HCs (median ≤ 5 fg/ml, P < 0.001) and SSc (median 11.6 fg/ml, P = 0.043), lower compared with SLE (median 313.5 fg/ml, P = 0.068) and positively correlated with blood ISG expression (r = 0.66–0.94, P < 0.001). Comparable to MxA ELISA [area under the curve (AUC) 0.93], IFN-α2 measurement using Simoa identified pSS with high ISG expression (AUC 0.90) with 80–93% specificity and 71–84% sensitivity. Blinded validation in an independent pSS cohort yielded a comparable accuracy. Multiple regression indicated independent associations of autoantibodies, IgG, HCQ treatment, cutaneous disease and a history of extraglandular manifestations with serum IFN-α2 concentrations in pSS.

Conclusion. Simoa serum IFN-α2 reflects blood ISG expression in pSS, SLE and SSc. In light of IFN-targeting treatments, Simoa could potentially be applied for patient stratification or retrospective analysis of historical cohorts.

Key words: type I IFN, primary SS, Simoa, SLE, SSc

Rheumatology key messages

- Serum IFN-α2 measured by Simoa immunoassay is elevated in primary SS, SSc and SLE.
- IFN-α2 positively correlates with blood IFN-stimulated gene and protein expression.
- IFN-α2-Simoa demonstrates high replicability, but the IFN-stimulated genes score has a greater ability to distinguish pSS from controls.

1Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, 2Department of Applied Biomarkers and Immunoassays, NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany, 3Department of Internal Medicine, Division of Clinical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, 4Department of Clinical Sciences Malmö, Division of Rheumatology, Lund University, Malmö, Sweden and 5Laboratory Medical Immunology, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

Submitted 2 April 2021; accepted 3 September 2021

Correspondence to: Marjan A. Versnel, Department of Immunology, Erasmus MC, University Medical Center Rotterdam, P.O Box 2040, 3000 CA Rotterdam, The Netherlands.
E-mail: m.versnel@erasmusmc.nl.

*Willem A. Dik and Marjan A. Versnel contributed equally to this study.
Introduction

Sustained systemic activation of the type I IFN (IFN-I) pathway is a well-known pathophysiological feature of several systemic autoimmune diseases (SADs), including SLE, primary SS (pSS) and SSc [1]. Therapeutic strategies targeting IFN-I are under clinical evaluation. Anifrolumab, a blocking antibody against the IFN-I receptor (IFNAR), has recently been found to induce clinically relevant responses in patients with active SLE [2–4]. Measurement of IFN-I will likely assist in the selection of candidates for these targeted treatments, urging the development and validation of robust and easy-to-perform assays.

The IFN-I family comprises 16 protein subtypes that have important antiviral and immunomodulatory properties [5–7]. These functions are largely effectuated by signaling through the IFNAR complex. The diversity of subtypes and the low circulating levels complicate quantification of IFN-I protein in biological samples by routinely used laboratory techniques such as ELISA.

Various methods measuring different elements of the IFN pathway are being used to evaluate IFN-I pathway activation. The majority of these assays exploit downstream cellular responses to IFN by quantification of expression of either IFN-stimulated genes (ISGs) or proteins. The development of ultrasensitive single-molecule array (Simoa) digital ELISA technology has facilitated the direct measurement of IFN-α protein levels [8, 9].

At present, a handful of studies have been published employing this ultrasensitive technique in patients with monogenic interferonopathies or SLE, while application in other SADs has been limited [8, 10–13]. Most of these studies use custom homebrew assays developed with autoantibodies specific for all IFN-α subtypes cloned from patients with autoimmune polyglandular syndrome type 1 (APS1) [8, 10, 13].

Here we tested the performance of a commercially available ready-to-use Simoa immunoassay kit for quantification of IFN-α2 protein concentrations in serum from two independent and clinically well-characterized pSS cohorts and compared the IFN-α2 protein levels to those in SLE and SSc patients. Additionally, a side-by-side comparison of serum IFN-α2 with whole blood ISG expression, intracellular myxovirus resistance protein 1 (MxA) protein levels and serum IFN-I bioactivity was performed in these cohorts.

Methods

Patients and healthy controls (HCs)

Patients with pSS (n = 85), SLE (n = 24) and SSc (n = 23) and HCs (n = 40) recruited at the Erasmus MC, University Medical Center Rotterdam, from which at least paired samples of serum and PAXgene material were stored, were included in this study (Rotterdam cohort). An established cohort of pSS patients (n = 110) recruited at the Department of Rheumatology, Lund University, Malmö, Sweden [14] and additional HCs (n = 28) recruited at the Erasmus MC were used as a validation cohort (Malmö cohort). This study was approved by the Medical Ethics Review Committees of the Erasmus MC (MEC-2011-116, MEC-2016-202) and Lund University (2015/311, 2017/94). In accordance with the Declaration of Helsinki, written informed consent was obtained from all participants. Further details are provided in Supplementary Data S1, available at Rheumatology online.

Ultrasonic IFN-α Simoa

IFN-α2 was measured in duplicates from serum samples (diluted two-fold in sample diluent) using the Simoa IFN-α Advantage Kit (no. 100860, Quanterix, Billerica, MA, USA) following the instructions of the supplied manual. Sample processing and analysis were done using an HD-X analyser (software version 1.6.1905.300; Quanterix). The lower limit of detection was 5 fg/ml.

Recombinant IFN-I subtypes

To verify the analytical specificity of the Simoa IFN-α Advantage Kit and HEK293-3C11-ISRE reporter cells, serum of an HC or special stripped serum (Valley Advantage Kit and HEK293-3C11-ISRE reporter cells, Winchester, VA, USA) were spiked with recombinant human IFN-α1(D), -α2(D), -α2(2n), -α4(M1), -α4(14), -α5(5), -α6(6), -α7(7), -α8(8), -α16.4(16), -α16.7(17), -α19(19), IFN-β1a (all from PBL Assay Science, Tebu-bio, Heerhugowaard, The Netherlands) or IFN-γ (PeproTech, Cranbury, NJ, USA) and snap frozen or assayed directly.

Real-time PCR IFN-stimulated genes, MxA immunoassay and IFN-I reporter assay

Whole blood expression of ISGs MxA, IFI44, IFI44L, IFIT1, and IFIT3 was quantified from PAXgene Blood RNA tubes (PreAnalytiX, Becton Dickinson, Vianen, The Netherlands) by RT-PCR and an IFN-I score was calculated as previously described [15]. The threshold value for the IFN-I score was set to the 97.5th percentile of IFN-I scores in HCs, consistent with the intercept of fitted Gaussian density components in a finite mixture model and the local minimum of a non-parametric density estimate of IFN-I score data in autoimmune patients (Supplementary Fig. S1, available at Rheumatology online). Intracellular MxA protein was measured by an immunoassay (lower limit of detection 10 μg/l) as previously described [16–18]. IFN-I activity in serum was measured using pGreenFire-ISRE reporter construct-transduced HEK293-3C11 cells (kindly provided by Jan Rehwinkel, University of Oxford, Oxford, UK [19] and HCs peripheral blood mononuclear cells (PBMCs). Assay details are provided in Supplementary Data S1, available at Rheumatology online.

https://academic.oup.com/rheumatology
## Table 1 Demographic and clinical characteristics

| Characteristics                          | Rotterdam           | Malmo               | P-value |
|------------------------------------------|----------------------|---------------------|---------|
|                                          | HCs (n = 68)         | SLE (n = 24)        | SSc (n = 23) | pSS (n = 85) | pSS (n = 110) |
| **Demographics**                         |                      |                     |          |             |               |
| Female, n/N (%)                          | 62/68 (91.2)         | 22/24 (91.7)        | 20/23 (87.0) | 77/85 (90.6) | 102/110 (92.7) | 0.782 |
| Age, years, median (Q1–Q3)               | 51 (32.8–57)         | 49 (37–55)          | 61 (53–67.5) | 62 (53–68)  | 64.5 (47–72)  | 0.737 |
| **Patient characteristics, median (Q1–Q3)**|                      |                     |          |             |               |
| Disease duration, years                  | – 15 (7.5–19.3)      | – 11 (8–20.5)       | 12 (6–20.3) | 12 (5–21)  | 0.354 |
| Disease activity<sup>a</sup>              | – 2 (0–4)            | –                   | 2 (0–7.25)  | 3 (1–7.75)  | 0.290 |
| Clinical disease activity<sup>b</sup>     | – 0 (0–1)            | –                   | 2 (0–9.25)  | 2 (0–8)    | 0.763 |
| **Laboratory parameters**                |                      |                     |          |             |               |
| ANA, n/N (%)                             | – 24/24 (100)        | 18/21 (91.3)        | 68/85 (80)  | 89/110 (80.9) | 1.000 |
| Anti-SSA, n/N (%)                        | – 12/24 (50)         | –                   | 72/85 (84.7) | 95/110 (86.4) | 0.903 |
| Anti-Ro52, n/N (%)                       | – –                  | –                   | 64/72 (88.9) | 70/82 (85.4) | 0.939 |
| Anti-Ro60, n/N (%)                       | – –                  | –                   | 66/72 (91.7) | 78/82 (95.1) | 0.234 |
| Anti-SSB, n/N (%)                        | – 7/24 (29.2)        | –                   | 48/85 (56.5) | 63/110 (57.3) | 1.000 |
| Anti-dsDNA, IU/mL, median (Q1–Q3)        | – 14.5 (1.63–39.5)   | –                   | –          | –          | –             |
| Anti-Sm, n/N (%)                         | – 5/24 (20.8)        | –                   | –          | –          | –             |
| Anti-RNP, n/N (%)                        | – 9/24 (37.5)        | –                   | –          | –          | –             |
| IgG, g/L, median (Q1–Q3)                 | – 1.08 (0.89–1.17)   | –                   | 1.16 (1.03–1.30) | 0.33 (0.81–1.07) | <0.001 |
| C3, g/L median (Q1–Q3)                   | – 0.19 (0.14–0.22)   | –                   | 0.19 (0.14–0.23) | 0.17 (0.13–0.22) | 0.137 |
| **Current medication, n/N (%)**          |                      |                     |          |             |               |
| HCQ                                      | – 17/24 (70.8)       | 2/23 (8.7)          | 42/85 (49.4) | 35/110 (31.8) | 0.019 |
| HCQ monotherapy                          | – 4/17 (23.5)        | 1/2 (50)            | 35/42 (83.3) | 17/35 (48.6) | 0.003 |
| HCQ + corticosteroids/DMARDs/biologics   | – 13/17 (76.5)       | 1/2 (50)            | 7/42 (16.7)  | 18/35 (51.4) |               |
| Corticosteroids/DMARDs                   | – 18/24 (75)         | 13/23 (56.5)        | 12/85 (14.1) | 29/110 (26.4) | 0.057 |
| Corticosteroids + DMARDs                 | – 2/18 (11.1)        | 1/13 (7.7)          | 2/12 (16.7)  | 6/29 (20.7)  | –             |
| Corticosteroids only                     | – 10/18 (55.6)       | 5/13 (38.5)         | 9/12 (75)   | 22/29 (75.9) | –             |
| DMARDs only                              | – 6/18 (33.3)        | 7/13 (53.8)         | 1/12 (8.3)   | 1/29 (3.5)   | –             |
| Rituximab                                | – 0/24 (0)           | 0/23 (0)            | 0/85 (0)    | 8/110 (7.3)  | –             |
| Belimumab                                | – 2/24 (8.3)         | 0/23 (0)            | 1/85 (1.2)   | 0/110 (0)    | –             |

<sup>a</sup>Disease activity: ESSDAI for pSS and SLEDAI-2K for SLE. <sup>b</sup>Clinical disease activity: ClinESSDAI for pSS and ClinSLEDAI for SLE. Mann–Whitney U test or Pearson’s chi-squared test were used to compare medians or frequencies of the Rotterdam and Malmö pSS cohorts. anti-Sm: anti-Smith; Q1: quartile 1; Q3: quartile 3.
Statistical analysis

Statistical analyses were performed in R (version 3.6.3; R Foundation for Statistical Computing, Vienna, Austria) [20] using the clickr (Censoring Data and Likelihood-Based Correlation Estimation) package (version 1.0) for correlation analysis [21], the pROC package (version 1.16.2) for receiver operating characteristics (ROC) analysis [22] and the CensReg (Censored Regression Tobit Models) package (version 0.5-30) for bivariate and multivariable regression analysis [23].

Results

Simoa IFN-α Advantage Kit primarily detects IFN-α2

To assess the analytical specificity of the Simoa IFN-α Advantage Kit, serum from an HC was spiked with 1 of 15 recombinant IFN-α subtypes, IFN-β or IFN-γ. Quantification indicated efficient detection of IFN-α2 subvariants in contrast to detection of IFN-α4a, IFN-α6 and IFN-α10 only at the highest concentration tested (>1500 fg/ml) (Supplementary Fig. S2, available at Rheumatology online).

Serum IFN-α2 concentrations are elevated in pSS, SLE and SSc

Detectable concentrations of IFN-α2 were present in 75.3% of serum samples from pSS (Rotterdam cohort), 75% from SLE, 56.5% from SSc and 45% from HCs. Serum IFN-α2 concentrations were elevated in pSS (Rotterdam cohort; median 61.3 fg/ml) compared with HCs (median ≤5 fg/ml, P < 0.001) and SSc (median 11.6 fg/ml, P = 0.043) (Fig. 1A). The highest IFN-α2 concentrations were observed in serum from SLE patients (median 313.5 fg/ml). SLE patients in remission (according to the Definitions of Remission in SLE classification [24]) showed significantly lower (P = 0.015) serum IFN-α2 concentrations compared with patients not in remission (Supplementary Fig. S3, available at Rheumatology online), which is in line with previous observations [8, 11, 12].

Serum IFN-α2 yields lower accuracy in discriminating pSS from HCs than ISG expression

Next we compared serum IFN-α2 with a whole blood 5 ISG–based transcript score (IFN-I score) reflecting in vivo IFN-I bioactivity. In the same cohort we also assessed whole blood intracellular MxA protein concentrations by an immunoassay that we previously described to be highly correlated with the IFN-I score in both pSS and SLE patients [16, 17]. The IFN-I score and intracellular MxA concentrations in pSS, SLE and SSc followed a similar pattern as serum IFN-α2 (Fig. 1B, C). The diagnostic accuracy of serum IFN-α2 to discriminate between pSS and HCs was evaluated by ROC analysis. The area under the curve (AUC) was lower for serum IFN-α2 (AUC = 0.77) compared with the IFN-I score (AUC = 0.86, P = 0.019) and intracellular MxA (AUC = 0.85, P = 0.036) (Supplementary Fig. S4A, available at Rheumatology online). The Youden’s J index summarizes the overall diagnostic performance of a test as a value between 0 (no diagnostic value) and 1 (perfect test) by integrating sensitivity and specificity with equal weight and can be used as a criterion for selection of optimal cut-off values. A maximum Youden’s J index of 0.54 was reached at a threshold of 19.3 fg/ml serum IFN-α2 (Supplementary Fig. S4B, available at Rheumatology online), yielding 62% sensitivity and 90% specificity (Supplementary Table S2, available at Rheumatology online).

Serum IFN-α2 is positively correlated with whole blood ISG expression and serum IFN-I bioactivity

Serum IFN-α2 concentrations were positively correlated with IFN-I score (r = 0.66, P < 0.001), intracellular MxA protein levels (r = 0.75, P < 0.001) and expression of individual ISG transcripts in pSS (Fig. 1D and E; Supplementary Fig. S5A, available at Rheumatology online). In SLE and SSc patients, similar correlations between the IFN-I score and serum IFN-α2 were observed, with the highest correlation coefficients in SLE (Fig. 1F–I; Supplementary Fig. S5B and C, available at Rheumatology online). A different method to assess bioactive IFN-I in serum is an IFN-α/β luciferase reporter assay (Supplementary Fig. S6A, available at Rheumatology online). In this assay, ISG-inducing capacity of patients’ sera was observed only for a minority of samples, mostly derived from SLE patients (Supplementary Fig. S6B, available at Rheumatology online). Taking an alternative approach using HC PBMCs, SLE sera induced higher levels of IFNAR-dependent ISG expression compared with pSS sera (Supplementary Fig. S6C, available at Rheumatology online). The IFN-I bioactivity in SLE sera positively correlated with serum IFN-α2 (r = 0.62, P < 0.001), IFN-I score (r = 0.61, P < 0.001) and MxA levels (r = 0.51, P = 0.009) (Supplementary Fig. S6D, available at Rheumatology online).

Serum IFN-α2 identifies pSS with high ISG expression

The IFN-I scores in pSS patients follow a bimodal distribution on the basis of which patients were classified as IFN-low or IFN-high. As expected, IFN-α2 concentrations were significantly higher in IFN-high compared with IFN-low pSS (Fig. 2A). ROC analysis indicated comparable discriminative ability of serum IFN-α2 (AUC = 0.9) and intracellular MxA (AUC = 0.93) to identify IFN-high pSS patients (Fig. 2B). The maximum accuracy of 83.7% and maximum Youden’s J index of 0.67 were obtained for serum IFN-α2 at a threshold of 19.8 fg/ml and only changed marginally when increasing the threshold to 28 or 66 fg/ml (Supplementary Fig. S7, available at Rheumatology online; Table 2). Using these thresholds, sensitivity ranged from 71 to 84% and specificity from 80 to 93%. Blinded validation in the second, independently collected pSS cohort (Malmö cohort) expanded with 28 additional HCs confirmed the measures of discriminative property and predictive ability of
serum IFN-α2 (Table 2; Supplementary Table S2, available at Rheumatology online). Notably, serum IFN-α2 data, IFN-I scores and the correlation between them were replicable in two sets of HCs and pSS patients from both cohorts despite independent sample collection, processing and measurement (Supplementary Fig. S8, available at Rheumatology online). A total of 15 pSS patients from both cohorts that were classified as IFN-high based on their IFN-I score exhibited serum IFN-α2 concentrations <19 fg/ml. In comparison to IFN-high pSS with IFN-α2 >19 fg/ml, these patients had lower IFN-I scores, intracellular MxA and total IgG and were more frequently negative for ANA and anti-SSB autoantibodies (Supplementary Table S3, available at Rheumatology online). No differences between these groups were observed in the use of medication, complement factors, disease activity and age.

Serum IFN-α2 is associated with serological disease and HCQ treatment in pSS

Bivariate analyses indicated higher serum IFN-α2 concentrations in pSS patients with autoantibodies and lower IFN-α2 in patients currently treated with HCQ (Table 3). Serum IFN-α2 was positively correlated with total IgG levels in both cohorts and negatively correlated with disease activity.
with complement components C3 and C4 in the Rotterdam cohort (Table 3). Neither total EULAR SS Disease Activity Index (ESSDAI) score [25] nor the number of active ESSDAI domains were significantly correlated with serum IFN-$\alpha_2$ (Table 3; Supplementary Table S4, available at Rheumatology online). Considering each ESSDAI domain separately, active involvement of haematological or cutaneous domains was associated with higher IFN-$\alpha_2$ (Supplementary Table S4, available at Rheumatology online). No differences in serum IFN-$\alpha_2$ were observed between patients with active cutaneous vasculitis/purpura ($n=4$) and patients with subacute cutaneous lupus erythematosus ($n=5$) (data not shown). In contrast, patients with active articular involvement had lower IFN-$\alpha_2$ levels (Supplementary Table S4, available at Rheumatology online). Multivariable regression analysis was performed on the pooled data from both cohorts to increase statistical power. Multiple regression revealed independent associations of total IgG levels, autoantibodies, use of HCQ and activity in articular and cutaneous ESSDAI domains, but not total ESSDAI score or the number of active ESSDAI domains with serum IFN-$\alpha_2$ in pSS (Table 3; Supplementary Table S4, available at Rheumatology online).

Higher serum IFN-$\alpha_2$ in pSS with extra-epithelial extraglandular manifestations (EGMs)

Patients with EGMs are at higher risk for morbidity and mortality [26–28]. We evaluated the association between serum IFN-$\alpha_2$ and EGMs defined as current or past pSS-related systemic involvement in any of the organ-specific ESSDAI domains. Although a trend for higher IFN-$\alpha_2$ was observed in pSS with EGMs compared with patients with exclusive glandular disease, this difference did not reach statistical significance (Supplementary Table S5, available at Rheumatology online). Based on the underlying pathophysiological mechanisms, EGMs

Table 2 Measures of accuracy of serum IFN-$\alpha_2$ to identify IFN-high pSS

| Measure | Rotterdam | Validation in Malmö cohort |
|---------|-----------|----------------------------|
|         | 19 fg/mL  | 28 fg/mL | 66 fg/mL | 19 fg/mL | 28 fg/mL | 66 fg/mL |
| Accuracy | 0.83 (0.74, 0.90) | 0.83 (0.74, 0.91) | 0.79 (0.70, 0.87) | 0.89 | 0.89 | 0.76 |
| Sensitivity | 0.84 (0.75, 0.93) | 0.80 (0.70, 0.91) | 0.71 (0.59, 0.82) | 0.92 | 0.91 | 0.73 |
| Specificity | 0.80 (0.63, 0.93) | 0.87 (0.73, 0.97) | 0.93 (0.83, 1) | 0.81 | 0.85 | 0.89 |
| NPV | 0.73 (0.61, 0.86) | 0.70 (0.60, 0.83) | 0.63 (0.54, 0.74) | 0.75 | 0.73 | 0.50 |
| PPV | 0.89 (0.81, 0.96) | 0.92 (0.85, 0.98) | 0.95 (0.88, 1) | 0.94 | 0.95 | 0.95 |

Data represent measures of accuracy (95% CI) calculated from the ROC analysis of the Rotterdam cohort (pSS, $n=85$; HCs, $n=40$) and blinded validation of the presented threshold values in the Malmö cohort (pSS, $n=110$) extended with 28 additional HCs. NPV: negative predictive value; PPV: positive predictive value.
| Variables                  | Bivariate analysis | Multivariable analysis |
|---------------------------|--------------------|------------------------|
|                           | Rotterdam          | Malmö                  |                           |
|                           | Serum IFN-α2       | Serum IFN-α2           | Estimate | Standard error | P-value |
|                           | P-value            | P-value                |          |               |         |
| Intercept                 | 1.647              | 0.909                  | 0.070    |               |         |
| ESSDAI score              | 0.166*             | 0.139                  | 0.014*   | 0.889         | 0.017   | 0.024   | 0.482    |
| Age                       | −0.158*            | 0.156                  | −0.122*  | 0.199         | −0.015  | 0.009   | 0.116    |
| Gender                    | 0.349              | 0.349                  | 0.933    | 0.332         | 0.469   | 0.479    |
| Female                    | 49.9 (45–185.8)    | 80.9 (15.3–308.3)      | <0.001   | 0.092         | 0.027   | <0.001  |
| Male                      | 88.9 (49.3–188.9)  | 102.3 (28.2–265.5)     | <0.001   | 0.092         | 0.027   | <0.001  |
| IgG                       | 0.552*             | <0.001                 | 0.367*   | 0.046*        | 0.629   | 0.050   | 0.656    | 0.939    |
| C3                        | −0.249*            | 0.026                  | −0.046*  | 0.629         | −0.050  | 0.656   | 0.939    |
| C4                        | −0.317*            | 0.004                  | −0.089*  | 0.351         | −0.887  | 2.434   | 0.716    |
| HCQ                       | 0.056              | 0.038                  | −1.068   | 0.270         |         |         | <0.001   |
| No                        | 88 (11.4–243.5)    | 90.5 (37.8–330.5)      |         |               |         |         |         |
| Yes                       | 30 (5–124)         | 47 (7–110.4)           |         |               |         |         |         |
| Corticosteroids           | 0.777              | 0.676                  | 0.355    | 0.350         | 0.311   |         |         |
| No                        | 61.3 (5.1–179.9)   | 84.5 (13.2–259.3)      |         |               |         |         |         |
| Yes                       | 95.2 (9.5–192)     | 64.9 (41.7–506.7)      |         |               |         |         |         |
| DMARDs                    | 0.722              | 0.485                  | 0.444    | 0.636         | 0.486   |         |         |
| No                        | 67.9 (6.2–185.9)   | 79.5 (13.3–286.1)      |         |               |         |         |         |
| Yes                       | 19.3 (12–221.2)    | 118.8 (64.9–467.8)     |         |               |         |         |         |
| ANA                       | <0.001             | <0.001                 | 1.040    | 0.407         | 0.011   |         |         |
| Negative                  | 7.2 (5–73.9)       | 95.5 (42.7–405.5)      |         |               |         |         |         |
| Positive                  | 91 (16.1–218.9)    | <0.001                 | 1.411    | 0.450         | 0.002   |         |         |
| SSA                       | <0.001             | <0.001                 | 0.765    | 0.295         | 0.010   |         |         |
| Negative                  | 6.1 (5–26.8)       | 37.5 (6.2–148.5)       |         |               |         |         |         |
| Positive                  | 122 (57.6–253.7)   | 90.5 (61.1–427.4)      |         |               |         |         |         |
| Storage years             | −0.188*            | 0.283                  | −0.145   | 0.108         | 0.179   |         |         |

Bivariate analysis: data represent *correlation coefficients or **medians (Q1–Q3) of IFN-α concentrations (fg/mL) in pSS patients from the Rotterdam and Malmö cohorts. Correlations between log(IFN-α) and indicated variables were assessed by likelihood-based correlation coefficient estimation. Multivariable analysis: independent associations of indicated variables with log(IFN-α) in the pooled cohort were evaluated in a censored regression (tobit) model. For both cohorts, absolute C3 levels were centralized before inclusion in multivariable analysis. Bold values denote statistical significance at the $p < 0.05$ level.
were further classified into peri-epithelial (pulmonary, central nervous system, muscular, renal: tubulointerstitial nephritis), extra-epithelial (cutaneous, peripheral nervous system, lymphadenopathy, haematological, renal: glomerulonephritis) and non-specific (constitutional, articular) [29, 30]. Current or past extra-epithelial EGMs, but not peri-epithelial or non-specific EGMs, were associated with higher IFN-α2 concentrations and a positive correlation was observed between the number of extra-epithelial EGM domains and serum IFN-α2 (Supplementary Fig. S9, available at Rheumatology online). This association remained significant in a multivariable regression analysis adjusting for peri-epithelial and non-specific EGMs, current use of medication, age, gender and serological parameters (Supplementary Table S6, available at Rheumatology online). Considering the individual extra-epithelial EGM domains, median IFN-α2 levels were higher in patients with a history of one or a combination of cutaneous (69% cutaneous vasculitis), haematological or lymphadenopathy (including lymphoma) domains, but not the peripheral nervous system domain, compared with patients without a history in any of the extra-epithelial domains (Supplementary Fig. S9, available at Rheumatology online).

Discussion

IFN-I pathway activation is a well-known feature in multiple SADs, but direct ultrasensitive measurement of IFN-α protein has been very limited in patients with SADs other than SLE. Using a commercially available Simoa IFN-α immunoassay kit, we found elevated levels of circulating IFN-α2 protein in two independent cohorts of pSS patients and patients with SSc and SLE. In pSS, SLE and SSc, these IFN-α2 protein levels were positively correlated with blood ISG transcript and MxA protein expression, commonly used as surrogate markers for IFN-I pathway activation. These correlations were strongest in SLE patients. In SLE, we found higher IFN-α2 levels in patients not in remission and additionally observed high IFN-α2 levels in a proportion of patients in remission. These data confirm previous observations that linked high levels of serum IFN-α to active disease and risk of relapse [8,11,12]. The results obtained from two independent pSS cohorts were highly comparable, indicating good replicability of IFN-α2 measurements between cohorts. Regression analysis did not show a significant negative association between IFN-α2 and the duration of serum storage in this cross-sectional cohort. This indicates that IFN-α2 protein levels in serum were relatively stable for up to 6 years (−80°C) as occurred in our study. Hence this technique is applicable for retrospective analysis of historical cohorts from which only serum is stored.

Ultrasensitive IFN-α protein measurement has well-defined specificity. In this study we used the sole commercially available IFN-α Simoa kit, which we verified to primarily detect IFN-α2, one of the most potent inducers of ISG expression of the IFN-α subtypes [31]. Others have used homebrew Simoa assays with high-affinity antibodies, cloned from APS1 patients, that recognize all IFN-α subtypes [8,10,13]. However, these antibodies are currently not commercially available. Using these antibodies, the authors reported a positive correlation between serum IFN-α concentrations and ISG expression score in SLE patients [8]. Here we show similar correlations between blood ISG score and serum IFN-α2. Although the timing and magnitude of expression may vary between the different human IFN-A genes, IFN-α2 seems to be expressed exclusively in parallel with other IFN-α subtypes [32,33]. The analogous results obtained by two Simoa assays with distinct specificities and the current knowledge on human IFN-α biology suggest co-expression of multiple IFN-α subtypes contributing to ISG expression in patients with SADs. A gold standard capturing the entirety of the concept IFN-I pathway activation does not exist. Measurement of ISGs is the most frequently used method, but interpretation of this method for IFN-I specificity has been complicated by the significant overlap between gene expression modules that are activated by distinct IFN receptor complexes and even IFN-independent signalling [34–38]. Nevertheless, attempts have been made to define gene modules preferentially regulated by IFN-I or IFN-II [39,40]. The five genes of the composite ISG score that we used here belong to an IFN module induced in vivo upon treatment with recombinant IFN-α or IFN-β and upregulated in vitro preferentially by IFN-I over IFN-II [39]. This ISG score showed an excellent correlation with circulating IFN-α2 protein.

A small subset of pSS patients, mainly characterized by overall milder serological disease activity, exhibited a discrepancy between ISG expression score and IFN-α2 levels. Therefore, in accordance with studies in SLE, whole blood ISG expression seems to be a more sensitive method for IFN-I activation in patients with low levels of IFN-α [8,11]. It should be noted, however, that altered distribution of leucocyte subsets, a known phenomenon in autoimmune diseases, can cause variation in whole blood ISG expression [41]. The absence of elevated IFN-α2 in serum while ISG expression was positive might be explained by high-affinity binding of low levels of IFN-α to the membrane-bound IFNAR inducing transcriptional responses in vivo [42]. Alternatively, these patients may have increased concentrations of IFN-α subtypes or other type I IFNs not quantified by this Simoa assay. Conversely, apparent discordant measurements of high IFN-α2 and a low IFN-I score were found in only a few samples with similar frequency in pSS and HCs. As this might be caused by autoantibodies against IFN-α that could potentially have neutralizing capacity, we analysed sera for the presence of anti-cytokine antibodies using a bead-based method described previously [43,44]. No autoantibodies against IFN-α2 could be detected in these samples, while these were readily detected in serum from an APS1 patient (Supplementary Fig. S10, available at Rheumatology online).
Compared with both ISG expression and direct IFN-α2 measurement, the IFN-I reporter assay was far less sensitive in our cohort, as was also reported by others [11]. Accounting for potential modulating factors in serum upstream of the IFNAR affecting cellular responses to IFN-I, reporter assays measure the bioactivity of IFN-I present in samples rather than the concentration of protein. These assays are limited by a poor sensitivity to detect low levels of IFN-I in patient samples and are hard to standardize for use in clinical practice.

In the two pSS cohorts, serum IFN-α2 concentrations were mainly associated with disease-relevant serological parameters IgG, autoantibodies and complement components. These results are consistent with previous literature describing associations between IFN-I pathway activation and haematological or serological parameters in pSS and other SADs [10, 15, 45–47]. In line with our findings from a placebo-controlled trial of HCQ in pSS and several cross-sectional cohorts [15, 17, 48, 49], we found an independent negative association of HCQ treatment with serum IFN-α2 protein concentrations in pSS. This indicates a persistent effect of HCQ on IFN-I pathway activation after long-term treatment. In addition, we found higher IFN-α2 levels in patients with active cutaneous disease and patients with a history of extra-epithelial manifestations. Extra-epithelial manifestations, in particular cutaneous vasculitis, and several specific serological parameters are well established risk factors for lymphoma in pSS [50]. A limitation of our study is that we were unable to study IFN-I in salivary gland biopsies and correlate these to peripheral IFN-I pathway activation and clinical manifestations in our patient cohorts. Considering our results and the link between IFN-I pathway activation and biological markers of disease activity in pSS, future studies should evaluate potential additional prognostic value of IFN-I measurement for risk stratification.

The current development and clinical evaluation of treatments directed against the IFN-I pathway and related signalling components urges identification of biomarkers for patient stratification. These markers for selection of treatment candidates should accurately reflect the pathway of interest, be useful for prediction of treatment responses and be feasible for application in clinical practice using robust methods that can be standardized across laboratories. A hypothetical marker suitable for monitoring treatment responses or clinical disease activity should additionally be susceptible to change over time. Direct quantification of serum IFN-α by Simoa has a well-defined specificity for the pathway of interest and can be easily standardized considering the automated analytical procedure. The potential clinical relevance of serum IFN-α for use in risk stratification, prediction of treatment responses or monitoring in individual patients of distinct SAD entities remains to be elucidated.

In conclusion, the whole blood ISG expression in pSS, SLE and SSC is closely linked to elevated concentrations of circulating IFN-α2. Direct measurement of IFN-α protein at low concentrations in biological samples has been a considerable step forward in understanding IFN-I pathway activation in SADs and may be relevant in light of patient stratification and targeted treatment.

Acknowledgements

The authors would like to thank Jan Rehwinkel for providing the HEK293-3C11 luciferase reporter cells, Matti Waris for providing the antibodies for the MxA immunoassay, Chris Ramakers for performing C3/C4 and IgG measurements, Angelique van Rijswijk for performing anti-cytokine autoantibody measurements and the Department of Biostatistics, Erasmus MC for advice on statistical analysis.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

Disclosure statement: The authors have declared no conflicts of interest.

Data availability statement

The data underlying this article are available in the article and in its online supplementary material, available at Rheumatology online.

Supplementary data

Supplementary data are available at Rheumatology online.

References

1. Crow MK, Offeriev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol 2019;14:369–93.
2. Furie RA, Morand EF, Bruce IN et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 2019;1:e208–19.
3. Morand EF, Furie R, Tanaka Y et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211–21.
4. Morand EF, Furie R, Bruce IN et al. OP0003 Early and sustained responses with anifrolumab treatment in patients with active systemic lupus erythematosus (SLE) in 2 phase 3 trials. Ann Rheum Dis 2020;79:2–3.
5. Sadler AJ, Williams BRG. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8:559–68.
6. Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol 2018;9:2061.
7. González-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125–35.
8. Rodero MP, Decalf J, Bondet V et al. Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med 2017;214:1547–55.
Serum interferon-α2 in Sjögren’s syndrome

9 Rissin DM, Kan CW, Campbell TG et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 2010;28:595–9.

10 Reynolds JA, Briggs TA, Rice GI et al. Type I interferon in patients with systemic autoimmune rheumatic disease is associated with haematological abnormalities and specific autoantibody profiles. Arthritis Res Ther 2019;21:147.

11 Mathian A, Mouriès-Martin S, Dorgham K et al. Monitoring disease activity in systemic lupus erythematosus with single-molecule array digital enzyme-linked immunosorbent assay quantification of serum interferon-α. Arthritis Rheumatol 2019;71:756–65.

12 Mathian A, Mouriès-Martin S, Dorgham K et al. Ultrasensitive serum interferon-alpha quantification during SLE remission identifies patients at risk for relapse. Ann Rheum Dis 2019;78:1669–76.

13 Lodi L, Melki I, Bondet V et al. Differential expression of interferon-alpha protein provides clues to tissue specificity across type I interferonopathies. J Clin Immunol 2021;41:603–9.

14 Olsson P, Bodewes ILA, Nilsson AM et al. Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren’s syndrome. Rheumatol Int 2019;39:1575–84.

15 Bodewes ILA, Al-Ali S, van Helden-Meeuwsen CG et al. Systemic interferon type I and type II signatures in primary Sjögren’s syndrome reveal differences in biological disease activity. Rheumatology (Oxford) 2018;57:921–30.

16 Huijsjer E, van Helden-Meeuwsen CG, Groot N et al. MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Rheumatology (Oxford) 2019;58:1302–3.

17 Maria NI, Brkcic Z, Waris M et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjögren’s syndrome. Ann Rheum Dis 2014;73:1052–9.

18 Vallittu AM, Erälinna JP, Ilonen J, Salmi AA, Waris M. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. Acta Neurol Scand 2008;118:12–7.

19 Bridgeman A, Maelfait J, Davenne T et al. Viruses transfer the antiviral second messenger cGAMP between cells. Science 2015;349:1228–32.

20 R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2020.

21 Li Y, Shedden K, Gillespie BW, Gillespie JA. clickcorrect: Censoring data and likelihood-based correlation estimation, version: 1.0. https://cran.r-project.org/web/pack ages/clickcorrex/ (20 September 2021, date last accessed).

22 Robin X, Turck N, Hainard A et al. pROC: display and analyze ROC curves, version: 1.6.2. 2020. https://cran.r-project.org/web/packages/pROC/ (20 September 2021, date last accessed).

23 Henningsen A. censReg: Censored regression (tobit) models, version: 0.5-30. https://cran.r-project.org/web/packages/censReg/index.html (20 September 2021, date last accessed).

24 van Vollenhoven R, Voskuyl A, Bertsias G et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017;76:554–61.

25 Seror R, Ravaud P, Bowman SJ et al. EULAR Sjögren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren’s syndrome. Ann Rheum Dis 2010;69:1103–9.

26 Zhang Y, Li M, Zhang L et al. Association between comorbidities and extraglandular manifestations in primary Sjögren’s syndrome: a multicenter cross-sectional study. Clin. Rheumatol 2020;39:2677–88.

27 Singh AG, Singh S, Matteson EL. Rate, risk factors and causes of mortality in patients with Sjögren’s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology 2016;55:450–60.

28 Brito-Zerón P, Kostov B, Solans R et al. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016;75:348–55.

29 Bartoloni E, Alunno A, Gerli R. Clinical features. In: Gerli R, ed. Sjögren’s syndrome: novel insights in pathogenic, clinical and therapeutic aspects. London: Elsevier Science, 2016:11–28.

30 Papa Vitali DN. C. Management of primary Sjögren’s syndrome: recent developments and new classification criteria. Ther Adv Musculoskelet Dis 2018;10:39–54.

31 Moll HP, Maier T, Zimmer A, Lavoie T, Brostjan C. The differential activity of interferon-alpha subtypes is consistent among distinct target genes and cell types. Cytokine 2011;53:52–9.

32 Génin P, Lin R, Hiscott J, Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009;29:3435–50.

33 Paul F, Pellegrini S, Uzé G. IFNA2: the prototypic human alpha interferon. Gene 2015;567:132–7.

34 Ivashkiv LB, Donlin LT. Regulation of type I interferon. Mol Sci 2019;20:1445.

35 Bhat MY, Solanki HS, Advani J et al. Comprehensive network map of interferon gamma signaling. J Cell Commun Signal 2018;12:745–51.

36 Stanifer ML, Pervolaraki K, Boulant S. Differential regulation of type I and type III interferon signaling. Int J Mol Sci 2019;20:1445.

37 Bartee E, Mohamed MR, Lopez MC, Baker HV, McFadden G. The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts. J Virol 2009;83:498–511.

38 Wang W, Xu L, Brandsma JH et al. Convergent transcription of interferon-stimulated genes by TNF-α and IFN-α augments antiviral activity against HCV and HEV. Sci Rep 2016;6:25482.

39 Chiche L, Jourde-Chiche N, Whalen E et al. Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II
interferon signatures. Arthritis Rheumatol 2014;66:1583–95.

40 Rusinova I, Forster S, Yu S et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013;41:D1040–6.

41 Becker AM, Dao KH, Han BK et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One 2013;8:e67003.

42 Piehler J, Thomas C, Garcia KC, Schreiber G. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol Rev 2012;250:317–34.

43 Meesilavvikkai K, Dik WA, Schrijver B et al. A novel heterozygous mutation in the STAT1 SH2 domain causes chronic mucocutaneous candidiasis, atypically diverse infections, autoimmunity, and impaired cytokine regulation. Front Immunol 2017;8:274.

44 Puel A, Döffinger R, Natividad A et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207:291–7.

45 Brkic Z, Maria NI, van Helden-Meeuwsen CG et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis 2013;72:728–35.

46 Emamian ES, Leon JM, Lessard CJ et al. Peripheral blood gene expression profiling in Sjögren’s syndrome. Genes Immun 2008;10:285–96.

47 Nezos A, Gravani F, Tassidou A et al. Type I and II interferon signatures in Sjögren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjögren’s related lymphomagenesis. J Autoimmun 2015;63:47–58.

48 Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA. Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sjögren’s syndrome in the JOQUER randomized trial. Rheumatology (Oxford) 2020;59:107–11.

49 Olsen NJ, McAloose C, Carter J et al. Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis 2016;2016:8791629.

50 Goules AV, Tzioufas AG. Primary Sjögren’s syndrome: clinical phenotypes, outcome and the development of biomarkers. Immunol Res 2017;65:331–44.